Roland Stocker received his training as a biochemist at the ETH Zürich (Switzerland), ANU (Canberra, Australia) and the University of California (Berkeley, USA). Following an appointment as Assistant Professor at the University of Berne (Switzerland), Roland moved permanently to Australia in 1988 where he worked as Group Leader at the Heart Research Institute for 13 years, as a Professor at the Centre for Vascular Research at the University of New South Wales for 5 years, before taking up a Professorial Chair at the University of Sydney in late 2006. [More...]

Roland Stocker received his training as a biochemist at the ETH Zürich (Switzerland), ANU (Canberra, Australia) and the University of California (Berkeley, USA). Following an appointment as Assistant Professor at the University of Berne (Switzerland), Roland moved permanently to Australia in 1988 where he worked as Group Leader at the Heart Research Institute for 13 years, as a Professor at the Centre for Vascular Research at the University of New South Wales for 5 years, before taking up a Professorial Chair at the University of Sydney in late 2006.

Since moving to Australia in 1988, the work of Roland's laboratory has received continuous funding from competitive national (NHMRC, ARC, NHF) and international agencies (NIH). For the last 12 years, he also received commercial research support, including major pharmaceutical companies. Roland has received several awards, including the inaugural Simon Wolff Contrarian Award for work on vitamin E, and several from the NHF for highest ranked grant applications. Highlights of the more than 80 invitations to present at international meetings include four presentations at Gordon Research Conferences, two at each FASEB Conferences, the Biennial Meetings of the International Society for Free Radical Research (ISFRR) and the International Symposia of Atherosclerosis, and presentations at a Harden Conference and the International Symposium on Organic Free Radicals. The many invitations to write reviews on the role of antioxidants and oxidants in atherosclerosis include one for the prestigious Journal Physiology Review.

Roland is recognized internationally as an expert in redox biology, particularly for his research on antioxidants, and mechanisms and prevention of atherosclerotic vascular disease. Roland's work on bilirubin as a natural antioxidant is now referred to in biochemistry textbooks and it has contributed to a change in the threshold at which hyperbilirubinemia is treated in clinics. His work on vitamin E has changed the handling of parenteral nutrition in NICUs in New Zealand/Australia, and it provides a scientific rationale for the overall lack of benefit of vitamin E supplements on cardiovascular disease outcome.

Roland has been an NHMRC Research Fellow since 1994, and a Senior Principal Research Fellow since 2001. He has been/is editorial board member of all major journals publishing in the area of redox biology (Archiv Biophys Biochem, Chem Res Toxicol, Free Radic Biol Med, Free Radic Res and Redox Report) and of J Lipid Res. He regularly reviews for international journals (average: 1 manuscript/week), national and international granting agencies and has been/is a member of RGICs/GRPs of NHMRC and NHF. In 2003, RS chaired NHMRC GRP7b in Cardiovascular/Renal/Sports Medicine.

Roland is an Adjunct Professor at Boston University, a Visiting Professor at the National University of Singapore, Past-President of SFRR Australasia, Chairman of the Scientific Advisory Committee of the International Coenzyme Q10 Association, and was a Committee member of the International HDL Research Award Program. He has been/is consultant for international pharmaceutical companies, has organized several national and international meetings, and initiated and was the Chairman of the first joint meeting of SFRR Australasia and Japan.

Most recently, Roland has been awarded a Professorial Research Fellowship and a Medical Foundation Fellowship from the University of Sydney. In 2007, he was the Paul Nestel Lecturer at the annual scientific meeting of the Australian Atherosclerosis Society; he successfully licensed IP related to a novel class of compounds with anti-atherosclerotic properties to a US-based pharmaceutical company for development; and he was elected Deputy Chairman of the International CoQ10 Association, and Chairman of the 6th International CoQ10 Conference (2009), the 5th Biennial Meeting of SFRR (Australasia and Japan, 2009), and the 8th International Congress on Heme Oxygenases (2013).

- - -

Principal Investigator since 1988

Publications: 241 since 1982, of which 185 are peer-reviewed, original research papers; 25 are invited reviews and articles, and 27 are book chapters.

Citations: over 16,000 including 5 Citation Classics (>500 citations); 33 cited more than 100 times; 81 more than 50 times, with an average of 67 citations per article.

Current h-Index: 62

Patents: 7

Grants: Total Competitive ~$17.4M since 2000 and 15 Commercial ($3M)

Plenary Talks and Personal Invitations at International Meetings: 97 (total), plus 23 invited lectures at National Meetings over the last 10 years. [Hide detail]